Clinical Trials

BreastGenitourinaryGynecologic

134 enrolled

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

40 enrolled

HER2-positive Metastatic Breast Cancer

NCT06997029 2026-03-16

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Phase 1 Recruiting

234 enrolled

Tumor-Agnostic

Neoplasms

NCT07368998 2026-03-16

optINAVO

Phase 2 Recruiting

80 enrolled

Breast Neoplasms

NCT06016738 2026-03-13

OPERA-01

510 enrolled

Breast Neoplasms

NCT06736704 2026-03-13

SNV4818 in Participants With Advanced Solid Tumors

320 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT07287917 2026-03-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

92 enrolled

BreastDermatologic

Breast Neoplasms, Melanoma

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

200 enrolled

Breast Neoplasms

NCT04572295 2026-03-11

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

51 enrolled

Phase 2/3 Enrolling by invitation

Acrocephalosyndactylia, Breast Neoplasms

NCT06506955 2026-03-11

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

15 enrolled

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT06065748 2026-03-09

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07405801 2026-03-09

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Phase 2 Recruiting

80 enrolled

Breast Neoplasms

NCT06979596 2026-03-06

OMAHA-015

Phase 2 Recruiting

250 enrolled

Tumor-Agnostic

Neoplasms

NCT07174336 2026-03-06

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Neoplasm Metastasis

NCT06257264 2026-03-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Phase 1 Recruiting

258 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06982521 2026-03-03

ReDiscover-2

540 enrolled

Breast Neoplasms

NCT05307705 2026-03-02

PIKASSO-01

193 enrolled

Breast Neoplasms

NCT05768139 2026-03-02

PIKALO-1

BreastGynecologicHead & Neck

720 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07389733 2026-03-02

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

Phase 1/2 Not yet recruiting

180 enrolled

Advanced Unresectable or Metastatic Breast Cancer of Adults

NCT01602380 2026-02-27

FALCON

Phase 3 Completed

462 enrolled 20 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT07109726 2026-02-27

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

BreastGastrointestinalGynecologicHead & Neck

205 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT01597388 2026-02-24

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

Phase 1 Completed

99 enrolled 61 charts

Advanced Metastatic Breast Cancer

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

NCT07408089 2026-02-24

KOMODO-1

Phase 1 Recruiting

96 enrolled

Breast Neoplasms

NCT05022342 2026-02-23

SPEAR

Completed

595 enrolled

Breast Neoplasms

NCT07288359 2026-02-23

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 3 Active not recruiting

205 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT05038735 2026-02-20

EPIK-B5

212 enrolled

Breast Neoplasms

NCT06998407 2026-02-20

AVZO-023-1001

380 enrolled

HR+/HER2- Breast Cancer

NCT07347600 2026-02-20

reaINAVO

Recruiting

500 enrolled